Sarepta's WMS data extends ELEVIDYS ambulatory evidence but does not resolve FDA or execution overhang

What happened

Sarepta presented new data at the 2026 World Muscle Society congress showing safety and clinically meaningful functional benefit of ELEVIDYS in older ambulatory patients with Duchenne (ages 8-12), a subgroup where decline is typically more rapid. This adds to the positive 3-year EMBARK topline results from January 2026 but does not address the master report's core concerns: the FDA boxed warning and ambulatory-only restriction, unresolved non-ambulatory shipment suspension, and persistent infusion throughput bottlenecks. The report rates SRPT a WAIT with conviction 3.2, citing fragile balance sheet ($865M cash as of Sep 2025) and fixed Arrowhead payments beginning Feb 2026. The new data may reinforce physician confidence in ambulatory use but offers no clarity on PMO accelerated-approval durability following the ESSENCE miss or competitive threats from RGX-202. Consequently, the market is likely to remain focused on Q1'26 ELEVIDYS catch-up metrics and any incremental FDA actions.

Implication

If the WMS data withstands peer review and resonates with regulators/payers, it could support ELEVIDYS durability and potentially expand use in older ambulatory patients, improving long-term revenue visibility. However, the PMO franchise faces real withdrawal risk under FDORA after ESSENCE failed statistical significance, which could erase a billion-dollar revenue stream. Competitors like REGENXBIO's RGX-202 and Solid's SGT-003 are advancing, threatening share even if Sarepta's clinical profile holds. Cash burn remains high: $865M at Sep 2025 plus $50M annual Arrowhead payments starting Feb 2026 likely necessitates further financing or restructuring. Thus, while the data is encouraging, it does not mitigate the binary regulatory and execution risks that justify the WAIT rating and cautious position sizing.

Thesis delta

The thesis remains unchanged: ELEVIDYS clinical benefit in ambulatory patients is already incorporated, and this new data is incremental rather than transformative. The primary value drivers—FDA action on PMOs, ELEVIDYS commercial cadence, and competitive displacement—are unresolved. The WAIT rating, attractive entry near $14, and trim above $26 remain appropriate.